NeoGenomics [NEO] vs Danaher [DHR] Detailed Stock Comparison
NeoGenomics
NASDAQ
Loading...
Danaher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: NeoGenomics wins in 4 metrics, Danaher wins in 14 metrics, with 0 ties. Danaher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | NeoGenomics | Danaher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -8.22 | 43.09 | NeoGenomics |
| Price-to-Book Ratio | 0.93 | 2.78 | NeoGenomics |
| Debt-to-Equity Ratio | 68.09 | 35.45 | Danaher |
| PEG Ratio | 32.30 | 24.22 | Danaher |
| EV/EBITDA | 1,640.89 | 21.40 | Danaher |
| Profit Margin (TTM) | -11.54% | 14.21% | Danaher |
| Operating Margin (TTM) | -16.56% | 20.12% | Danaher |
| EBITDA Margin (TTM) | N/A | 20.12% | N/A |
| Return on Equity | -8.57% | 6.68% | Danaher |
| Return on Assets (TTM) | -2.75% | 4.01% | Danaher |
| Free Cash Flow (TTM) | $-34.04M | $5.30B | Danaher |
| 1-Year Return | -70.30% | -26.29% | Danaher |
| Price-to-Sales Ratio (TTM) | 1.24 | 6.05 | NeoGenomics |
| Enterprise Value | $1.08B | $160.92B | Danaher |
| EV/Revenue Ratio | 1.60 | 6.70 | NeoGenomics |
| Gross Profit Margin (TTM) | 43.59% | 59.35% | Danaher |
| Revenue per Share (TTM) | $5 | $33 | Danaher |
| Earnings per Share (Diluted) | $-0.61 | $4.71 | Danaher |
| Beta (Stock Volatility) | 1.62 | 0.80 | Danaher |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
NeoGenomics vs Danaher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| NeoGenomics | -2.86% | -22.84% | -30.23% | -20.31% | -65.54% | -69.07% |
| Danaher | -1.38% | 3.08% | 3.27% | 2.34% | -8.56% | -11.24% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| NeoGenomics | -70.30% | -50.05% | -87.15% | -11.46% | 376.64% | 1,175.00% |
| Danaher | -26.29% | -20.65% | 12.03% | 233.32% | 677.70% | 983.32% |
Performance & Financial Health Analysis: NeoGenomics vs Danaher
| Metric | NEO | DHR |
|---|---|---|
| Market Information | ||
| Market Cap | $831.37M | $145.32B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 1,715,660 | 5,174,298 |
| 90 Day Avg. Volume | 1,882,183 | 4,196,543 |
| Last Close | $5.10 | $203.99 |
| 52 Week Range | $4.81 - $19.11 | $171.00 - $281.70 |
| % from 52W High | -73.31% | -27.59% |
| All-Time High | $61.57 (Feb 15, 2021) | $296.06 (Sep 06, 2021) |
| % from All-Time High | -91.72% | -31.10% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.08% | 0.03% |
| Quarterly Earnings Growth | 0.08% | -0.39% |
| Financial Health | ||
| Profit Margin (TTM) | -0.12% | 0.14% |
| Operating Margin (TTM) | -0.17% | 0.20% |
| Return on Equity (TTM) | -0.09% | 0.07% |
| Debt to Equity (MRQ) | 68.09 | 35.45 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.92 | $73.10 |
| Cash per Share (MRQ) | $2.78 | $4.13 |
| Operating Cash Flow (TTM) | $7.61M | $6.17B |
| Levered Free Cash Flow (TTM) | $-759,125 | $3.88B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: NeoGenomics vs Danaher
| Metric | NEO | DHR |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -8.22 | 43.09 |
| Forward P/E | 32.30 | 24.22 |
| PEG Ratio | 32.30 | 24.22 |
| Price to Sales (TTM) | 1.24 | 6.05 |
| Price to Book (MRQ) | 0.93 | 2.78 |
| Market Capitalization | ||
| Market Capitalization | $831.37M | $145.32B |
| Enterprise Value | $1.08B | $160.92B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.60 | 6.70 |
| Enterprise to EBITDA | 1,640.89 | 21.40 |
| Risk & Other Metrics | ||
| Beta | 1.62 | 0.80 |
| Book Value per Share (MRQ) | $6.92 | $73.10 |
Financial Statements Comparison: NeoGenomics vs Danaher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NEO | DHR |
|---|---|---|
| Revenue/Sales | $168.04M | $5.74B |
| Cost of Goods Sold | $94.79M | $2.23B |
| Gross Profit | $73.25M | $3.51B |
| Research & Development | $10.18M | $379.00M |
| Operating Income (EBIT) | $-27.83M | $1.27B |
| EBITDA | $-6.31M | $1.87B |
| Pre-Tax Income | $-25.66M | $1.13B |
| Income Tax | $266,000 | $175.00M |
| Net Income (Profit) | $-25.92M | $954.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NEO | DHR |
|---|---|---|
| Cash & Equivalents | $346.19M | $1.99B |
| Total Current Assets | $573.93M | $9.53B |
| Total Current Liabilities | $279.70M | $6.65B |
| Long-Term Debt | $400.58M | $15.98B |
| Total Shareholders Equity | $888.27M | $50.86B |
| Retained Earnings | $-351.70M | $44.91B |
| Property, Plant & Equipment | $366.10M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NEO | DHR |
|---|---|---|
| Operating Cash Flow | $735,000 | $1.47B |
| Capital Expenditures | $-4.50M | $-239.00M |
| Free Cash Flow | $-29.83M | $1.05B |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-1.08B |
Short Interest & Institutional Ownership Analysis
| Metric | NEO | DHR |
|---|---|---|
| Shares Short | 4.27M | 7.84M |
| Short Ratio | 2.18 | 2.08 |
| Short % of Float | 0.05% | 0.01% |
| Average Daily Volume (10 Day) | 1,715,660 | 5,174,298 |
| Average Daily Volume (90 Day) | 1,882,183 | 4,196,543 |
| Shares Outstanding | 128.15M | 719.10M |
| Float Shares | 127.06M | 637.22M |
| % Held by Insiders | 0.01% | 0.11% |
| % Held by Institutions | 0.98% | 0.82% |
Dividend Analysis & Yield Comparison: NeoGenomics vs Danaher
| Metric | NEO | DHR |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |